BACKGROUND AND OBJECTIVES: Many studies have shown that the +252A/G polymorphism in the lymphotoxin-α gene is implicated in susceptibility to non-Hodgkin lymphoma but with considerable variance of results. This study aimed to clarify the overall association between the +252A/G polymorphism in the lymphotoxin-α gene and non-Hodgkin lymphoma (NHL) risk by performing a meta-analysis.
MATERIALS AND METHODS: The Pubmed and Embase databases were searched for all studies relating to lymphotoxin-α +252A/G gene polymorphism and NHL risk. Data were retrieved and statistical analyses were performed using the Revman 5.1 and STATA 12.0 software.
RESULTS: Fourteen case-control studies with 25,098 subjects were included. There was no significant association between lymphotoxin-α +252A/G gene polymorphism and the risk of NHL in the all-combined analysis (OR = 1.08, 95%CI: 0.98-1.19 for GG+GA vs. AA; OR = 1.05, 95%CI: 0.95-1.25 for GG vs. GA+AA). In a subgroup analysis by ethnicity, increased NHL risk was found in North Americans (OR = 1.21, 95%CI: 1.05-1.39 for GG+GA vs. AA), no significant association with NHL risk was identified in Asians or Europeans; In a subgroup analysis by NHL subtype, a significantly increased risk was identified in diffuse large B cell lymphoma patients (OR = 1.20 95%CI: 1.11-1.29 for GG+GA vs. AA), but not for follicular lymphoma.
CONCLUSIONS: This meta-analysis suggested that the lymphotoxin-α +252A/G gene polymorphism is a risk factor for NHL in North Americans, and this polymorphism may contribute to diffuse large B cell lymphoma susceptibility. Future studies that include different types of NHL and ethnicities are needed to support and extend these observations.Free PDF Download
To cite this article
C. Cao, S. Liu, S.-F. Lou, T. Liu
The +252A/G polymorphism in the Lymphotoxin-α gene and the risk of non-Hodgkin lymphoma: a meta-analysis
Eur Rev Med Pharmacol Sci
Vol. 18 - N. 4